Bethesda system

Bethesda System is a system used for reporting cervical or vaginal cytologic diagnoses. It was first introduced in 1988 and later revised in 1991, 2001, and 2014. The system is named after Bethesda, Maryland, where the conference that established the system was held.

History

The Bethesda System was developed during a National Cancer Institute (NCI) workshop in Bethesda, Maryland in 1988. The goal was to provide a universal approach to cytology reporting, which would allow for better communication between laboratories, clinicians, and patients. The system was revised in 1991, 2001, and 2014 to incorporate new scientific understanding and improve clinical utility.

Structure

The Bethesda System has three main components: the specimen type, the general categorization, and the interpretation/result. The specimen type indicates the source of the cytologic material. The general categorization is an optional component that classifies the specimen as "satisfactory for evaluation" or "unsatisfactory for evaluation". The interpretation/result provides the diagnosis.

Usage

The Bethesda System is used worldwide for the reporting of cervical-vaginal cytology. It has been adopted by many countries due to its simplicity, clarity, and flexibility. The system allows for the easy exchange of information and comparison of data, which is crucial for patient care and research.

Criticism

Despite its widespread use, the Bethesda System has been criticized for its perceived complexity and subjectivity. Some clinicians and researchers argue that the system's categories are too broad and that its terminology is confusing. However, proponents of the system argue that these issues are outweighed by the benefits of standardization and improved communication.

See also

• Cervical cytology
• Pap test
• National Cancer Institute

• 
  Cytopathology of low-grade squamous intraepithelial lesion (LSIL)
• 
  High-grade squamous intraepithelial lesion
• 
  Adenocarcinoma on pap test
• 
  Thyroid cytopathology of Bethesda category III with clotting artifact
• 
  Thyroid cytopathology of Bethesda category IV
• 
  Thyroid cytopathology of Bethesda category V with intranuclear cytoplasmic inclusion
• 
  Thyroid cytopathology of Bethesda category V with nuclear groove
• 
  Cytopathology suspicious for Hürthle cell neoplasm